Atirmociclib Clinical Trials

4 actively recruiting trials across 4 locations

▲ +1 trial since May 2026

Also known as: CDK4i

Pipeline

Phase 1: 2Phase 2: 1Phase 1/2: 1

Top Sponsors

OnKure, Inc.1
Olema Pharmaceuticals, Inc.1
Hoffmann-La Roche1
AstraZeneca1

Indications

Breast Cancer4
Cancer4
Metastatic Breast Cancer2
PI3K Gene Mutation1
ER-positive Breast Cancer1

Gilbert, Arizona1 trial

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

Banner MD Anderson Cancer Center

Phase 1

Duarte, California1 trial

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

City of Hope

Phase 1/2

Encinitas, California1 trial

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

California Cancer Associates for Research and Excellence

Phase 1

St Louis, Missouri1 trial

Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer

Research Site

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.